HCW Biologics regained Nasdaq bid-price compliance, faces monitoring period
HCW Biologics received written notice on June 29, 2026, that the Nasdaq Hearings Panel found the company regained compliance with Listing Rule 5550(a)(2), the Bid Price Rule, as set forth in the Panel's decision letter dated May 29, 2026, as amended. The company is subject to a mandatory panel monitor through June 17, 2027; if it again falls out of compliance with the Bid Price Rule during that period, Nasdaq staff will issue a delisting determination letter without affording a cure or compliance period, and the company's securities may be delisted. The company plans to effect a one-for-six reverse stock split on June 30, 2026, to ensure long-term compliance with the minimum bid price requirement.
Key facts
- Nasdaq Hearings Panel found company regained compliance with Listing Rule 5550(a)(2) (Bid Price Rule) per Panel decision letter dated May 29, 2026, as amended
- Mandatory panel monitor in effect through June 17, 2027
- If company falls out of compliance with Bid Price Rule during monitoring period, Staff will issue Delist Determination Letter without permitting compliance plan or additional cure period
- Discretionary Panel Monitor to be imposed for one-year period from September 22, 2026, if remaining terms of decision are satisfied
- Reverse stock split at one-for-six ratio to be effected on June 30, 2026
Why it matters
HCW Biologics has cured a minimum-bid-price deficiency but remains under heightened scrutiny; any recurrence of the bid-price violation during the monitoring period will trigger immediate delisting proceedings without a standard cure period, creating material listing risk for the next year.
Share
Derived from 8-K filed 2026-06-30. Not investment advice. View the source filing on SEC.gov →